Zymeworks receives FDA Fast Track Designation for ZW191

Zymeworks (ZYME) announced that the U.S.FDA has granted Fast Track designation to ZW191, an antibody-drug conjugate targeting folate receptor-alpha, for the treatment of patients with advanced or metastatic platinum-resistant ovarian cancer. ZW191 is an ADC engineered to target FRalpha, a protein expressed in several tumor types, including approximately 75% of high-grade serous ovarian carcinomas, over 50% of endometrial cancers, and about 70% of lung adenocarcinomas4. ZW191’s differentiated design strongly supports its ability to internalize into FR-expressing cells with the potential to release bystander active topoisomerase-1 inhibitor, a novel proprietary payload developed by Zymeworks to kill tumor cells.